BAA_0600 is expressed in E. coli using a His-tagged expression vector, enabling affinity chromatography purification. The protein is lyophilized and provided in a sterile, ready-to-use format. Key specifications include:
Form: Lyophilized powder.
Stability: Stable at -20°C/-80°C when stored properly.
Handling Notes: Repeated freezing/thawing is discouraged; store working aliquots at 4°C for short-term use .
While BAA_0600 is annotated as a UPF0295 family protein, its specific biochemical functions remain poorly characterized in available literature. Limited data suggest potential involvement in pathways related to B. anthracis survival or pathogenicity, though no direct functional studies (e.g., enzymatic activity or interaction networks) are reported.
Pathway Involvement: No validated pathways are listed in current databases .
Interacting Proteins: No experimentally confirmed interactions are documented .
Role in Anthrax: Unlike protective antigen (PA) or spore proteins (e.g., BclA, BxpB), BAA_0600 is not directly linked to toxin production or immune evasion mechanisms .
BAA_0600 serves primarily as a research reagent for studying B. anthracis protein interactions, spore biology, or pathogenicity mechanisms. Potential applications include:
Structural Studies: Investigating the UPF0295 family’s role in bacterial physiology.
Antigen Screening: Testing BAA_0600 as a candidate in vaccine or diagnostic assays (though no efficacy data exists).
Protein-Protein Interactions: Identifying binding partners using co-IP or pull-down assays.
Functional Data: No published studies describe BAA_0600’s enzymatic activity, localization, or role in B. anthracis infection.
Vaccine Relevance: Unlike PA or spore antigens (e.g., BxpB), BAA_0600 is not implicated in immune protection or toxin neutralization .
Experimental Validation: Further studies are required to elucidate its biological significance.
KEGG: bai:BAA_0600